The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD

Details

  Created: Monday, 05 April 2021

Parish SJ, Cottler-Casanova S, Clayton AH, McCabe MP, Coleman E, Reed GM. The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. Sex Med Rev. 2021 Jan;9(1):36-56. doi: 10.1016/j.sxmr.2020.05.001. Epub 2020 Aug 13. PMID: 32800563.

Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data

Details

  Created: Monday, 05 April 2021

Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data. Lancet.2019.7(10):754-766. https://doi.org/10.1016/S2213-8587(19)30189-5.

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM)

Details

  Created: Wednesday, 03 May 2023

Simon, J. A., Goldstein, I., Kim, N. N., Davis, S. R., Kellogg-Spadt, S., Lowenstein, L., Pinkerton, J. V., Stuenkel, C. A., Traish, A. M., Archer, D. F., Bachmann, G., Goldstein, A. T., Nappi, R. E., & Vignozzi, L. (2018). The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause, 25(7), 837-847. https://doi.org/10.1097/GME.0000000000001138

Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause

Details

  Created: Wednesday, 03 May 2023

Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev 2018;6(4):558-571. DOI: 10.1016/j.sxmr.2018.03.005

Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review

Details

  Created: Wednesday, 03 May 2023

Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clinic Proceedings. 2017;92(1):114-128. http://dx.doi.org/10.1016/j.mayocp.2016.09.018

Disorders related to sexuality and gender identity in the ICD-11: revising the ICD-10 classification based on current scientific evidence, best clinical practices, and human rights considerations

Details

  Created: Wednesday, 03 May 2023

Reed GM, Drescher J, Krueger RB, Atalla E, Cochran SD, First MB, Cohen-Kettenis PT, Arango-de Montis I, Parish SJ, Cottler S, Briken P, Saxena S. Disorders related to sexuality and gender identity in the ICD-11: revising the ICD-10 classification based on current scientific evidence, best clinical practices, and human rights considerations. World Psychiatry. 2016 Oct;15(3):205-221. doi: 10.1002/wps.20354. Erratum in: World Psychiatry. 2017 Jun;16(2):220. PMID: 27717275; PMCID: PMC5032510.

Persistent Vulvar Pain Diagnostic and Treatment Algorithm

Details

  Created: Thursday, 03 March 2022

Click here to view & download.

International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

Details

  Created: Monday, 05 April 2021

Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, Park K, Stuenkel CA, Traish AM, Vignozzi L. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021 May;18(5):849-867. doi: 10.1016/j.jsxm.2020.10.009. Epub 2021 Apr 1. PMID: 33814355.

ISSWSH Review of Epidemiology and Pathophysiology, and a Consensus Nomenclature and Process of Care for the Management of Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD)

Details

  Created: Friday, 05 March 2021

Goldstein I, Komisaruk BR, Pukall CF, et al. International Society for the Study of Women’s Sexual Health (ISSWSH) Review of Epidemiology and Pathophysiology, and a Consensus Nomenclature and Process of Care for the Management of Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD). J Sex Med.2021;18(4):665-697.DOI: 10.1016/j.jsxm.2021.01.172

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

Details

  Created: Thursday, 05 November 2020

Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the Use of Testosterone Therapy for Women J Sex Med. 2019 Sep;16(9):1331-1337. doi:1016/j.jsxm.2019.07.012.PMID: 31488288

Mayo Clinic Proceedings - Hypoactive Sexual Desire Disorder (HSDD) ISSWSH Expert Consensus Panel Review

Details

  Created: Thursday, 05 November 2020

The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efficacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efficacy data. Menopausal women with HSDD may benefit from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efficacy and short-term safety. Currently, flibanserin is the only Food and Drug Administration–approved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD significantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments. Click here to read more.

Process of Care for the Identification of Sexual Concerns and Problems in Women

Details

  Created: Wednesday, 03 April 2019

Parish SJ, Hahn SR, Goldstein SW, Giraldi A, Kingsberg SA, Larkin L, Minkin MJ, Brown V, Christiansen K, Hartzell-Cushanick R, Kelly-Jones A, Rulle J, Sadovsky R, Faubion SS. The International Society for the Study of Women’s Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women. Mayo Clinic Proceedings. 2019;94(5):842-=856. https://doi.org/10.1016/j.mayocp.2019.01.009

Descriptors of Vulvodynia: A Multisocietal Definition Consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society)

Details

  Created: Monday, 01 April 2019

Bornstein J, Preti M, Simon JA, As-Sanie S, Stockdale CK, Stein A, Parish SJ, Radici G, Vieira-Baptista P, Pukall C, Moyal-Barracco M, Goldstein A; International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Womenʼs Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS). Descriptors of Vulvodynia: A Multisocietal Definition Consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society). J Low Genit Tract Dis. 2019 Apr;23(2):161-163. doi: 10.1097/LGT.0000000000000461. PMID: 30768446.

Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions

Details

  Created: Monday, 04 March 2019

Derogatis LR, San M, Balon R, Rosen R, Parish SJ. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions – Part I. Journal of Sexual Medicine. 2016;6(12):1881-1887. https://doi.org/10.1016/j.jsxm.2016.09.014

Parish SJ, Goldstein AT, Goldstein SW, Goldstein I, Pfaus J, Clayton AH, Giraldi A, Simon JA, Althof SE, Bachmann G, Komisaruk B, Levin R, Kellogg Spadt S, Kingsberg SA, Perelman MA, Waldinger MD, Whipple B. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions – Part II. Journal of Sexual Medicine. 2016;13(12):1888-1906. https://doi.org/10.1016/j.jsxm.2016.09.020

Parish SJ, Meston CM, Althof SE, Clayton AH, Goldstein I, Goldstein SW, Heiman JR, McCabe MP, Segraves RT, Simon SA. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III. J Sex Med 2019;16:452-462. DOI: 10.1016/j.jsxm.2019.01.010

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health

Details

  Created: Friday, 01 June 2018

Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018 Jun;25(6):596-608. doi: 10.1097/GME.0000000000001121. PMID: 29762200.

Process of Care for Management of Hypoactive Sexual Desire Disorder (HSDD) in Women

Details

  Created: Monday, 12 March 2018

Clayton AH, Goldstein I, Kim NN, Althof SE, Faubion SS, Faught BM, Parish SJ, Simon JA, Vignozzi L, Christiansen K, Davis SR, Freedman MA, Kingsberg SA, Kirana PS, Larkin L, McCabe M, Sadovsky R. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc. 2018 Apr;93(4):467-487. doi: 10.1016/j.mayocp.2017.11.002. Epub 2018 Mar 12. PMID: 29545008.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Womens Sexual Health and The North American Menopause Society

Details

  Created: Wednesday, 14 December 2016

Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. J Sex Med. 2014 Dec;11(12):2865-72. doi: 10.1111/jsm.12686. Epub 2014 Aug 25. PMID: 25155380.

2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia

Details

  Created: Friday, 01 April 2016

Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolnoun D, Coady D; consensus vulvar pain terminology committee of the International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Women's Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS). 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstet Gynecol. 2016 Apr;127(4):745-751. doi: 10.1097/AOG.0000000000001359. PMID: 27008217.